aluates Reports

$ 0.0

Automative

Global Oral Hypoglycemic Agents and Insulin Analogues Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-1C7107

Global Oral Hypoglycemic Agents and Insulin Analogues Market Insights and Forecast to 2028

BUY CHAPTERS

Global Oral Hypoglycemic Agents and Insulin Analogues Market Research Report 2025

Code: QYRE-Auto-1C7107

Report

September 2025

Pages:78

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Sanofi Aventis

Ganlee

Biocon Ltd.

Novo Nordisk

Eli Lilly

Tonghua Dongbao

United Laboratory

Jiangsu Wanbang

Oral Hypoglycemic Agents and Insulin Analogues Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Oral Hypoglycemic Agents and Insulin Analogues Market

The global market for Oral Hypoglycemic Agents and Insulin Analogues was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oral Hypoglycemic Agents and Insulin Analogues, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Hypoglycemic Agents and Insulin Analogues.

The Oral Hypoglycemic Agents and Insulin Analogues market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oral Hypoglycemic Agents and Insulin Analogues market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Oral Hypoglycemic Agents and Insulin Analogues manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Oral Hypoglycemic Agents and Insulin Analogues Market Report

Report Metric	Details
Report Name	Oral Hypoglycemic Agents and Insulin Analogues Market
CAGR	5%
Segment by Type	Insulin Secretagogues Alpha-glucosidase Inhibitors Insulin Sensitizers
Segment by Application	Hospitals Drug Store Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Sanofi-Aventis, Ganlee, Biocon, Novo Nordisk, Eli Lilly, Tonghua Dongbao, United Laboratory, Jiangsu Wanbang
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Hypoglycemic Agents and Insulin Analogues manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Hypoglycemic Agents and Insulin Analogues in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Oral Hypoglycemic Agents and Insulin Analogues Market report?

Ans: The main players in the Oral Hypoglycemic Agents and Insulin Analogues Market are Sanofi-Aventis, Ganlee, Biocon, Novo Nordisk, Eli Lilly, Tonghua Dongbao, United Laboratory, Jiangsu Wanbang

What are the Application segmentation covered in the Oral Hypoglycemic Agents and Insulin Analogues Market report?

Ans: The Applications covered in the Oral Hypoglycemic Agents and Insulin Analogues Market report are Hospitals, Drug Store, Others

What are the Type segmentation covered in the Oral Hypoglycemic Agents and Insulin Analogues Market report?

Ans: The Types covered in the Oral Hypoglycemic Agents and Insulin Analogues Market report are Insulin Secretagogues, Alpha-glucosidase Inhibitors, Insulin Sensitizers

1 Oral Hypoglycemic Agents and Insulin Analogues Market Overview

1.1 Product Definition

1.2 Oral Hypoglycemic Agents and Insulin Analogues by Type

1.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Value Comparison by Type (2024 VS 2031)

1.2.2 Insulin Secretagogues

1.2.3 Alpha-glucosidase Inhibitors

1.2.4 Insulin Sensitizers

1.3 Oral Hypoglycemic Agents and Insulin Analogues by Application

1.3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Value by Application (2024 VS 2031)

1.3.2 Hospitals

1.3.3 Drug Store

1.3.4 Others

1.4 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size Estimates and Forecasts

1.4.1 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue 2020-2031

1.4.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales 2020-2031

1.4.3 Global Oral Hypoglycemic Agents and Insulin Analogues Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Oral Hypoglycemic Agents and Insulin Analogues Market Competition by Manufacturers

2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Manufacturers (2020-2025)

2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Oral Hypoglycemic Agents and Insulin Analogues, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, Product Type & Application

2.7 Global Key Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, Date of Enter into This Industry

2.8 Global Oral Hypoglycemic Agents and Insulin Analogues Market Competitive Situation and Trends

2.8.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Oral Hypoglycemic Agents and Insulin Analogues Players Market Share by Revenue

2.8.3 Global Oral Hypoglycemic Agents and Insulin Analogues Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Oral Hypoglycemic Agents and Insulin Analogues Market Scenario by Region

3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region: 2020-2031

3.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region: 2020-2025

3.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region: 2026-2031

3.3 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region: 2020-2031

3.3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region: 2020-2025

3.3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region: 2026-2031

3.4 North America Oral Hypoglycemic Agents and Insulin Analogues Market Facts & Figures by Country

3.4.1 North America Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2020-2031)

3.4.3 North America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Oral Hypoglycemic Agents and Insulin Analogues Market Facts & Figures by Country

3.5.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2020-2031)

3.5.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Market Facts & Figures by Region

3.6.1 Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2020-2031)

3.6.3 Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Oral Hypoglycemic Agents and Insulin Analogues Market Facts & Figures by Country

3.7.1 Latin America Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2020-2031)

3.7.3 Latin America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Market Facts & Figures by Country

3.8.1 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2020-2031)

3.8.3 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2020-2031)

4.1.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2020-2025)

4.1.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2026-2031)

4.1.3 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2020-2031)

4.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2020-2031)

4.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2020-2025)

4.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2026-2031)

4.2.3 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2020-2031)

4.3 Global Oral Hypoglycemic Agents and Insulin Analogues Price by Type (2020-2031)

5 Segment by Application

5.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2020-2031)

5.1.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2020-2025)

5.1.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2026-2031)

5.1.3 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2020-2031)

5.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2020-2031)

5.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2020-2025)

5.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2026-2031)

5.2.3 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2020-2031)

5.3 Global Oral Hypoglycemic Agents and Insulin Analogues Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Sanofi-Aventis

6.1.1 Sanofi-Aventis Company Information

6.1.2 Sanofi-Aventis Description and Business Overview

6.1.3 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio

6.1.5 Sanofi-Aventis Recent Developments/Updates

6.2 Ganlee

6.2.1 Ganlee Company Information

6.2.2 Ganlee Description and Business Overview

6.2.3 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio

6.2.5 Ganlee Recent Developments/Updates

6.3 Biocon

6.3.1 Biocon Company Information

6.3.2 Biocon Description and Business Overview

6.3.3 Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Biocon Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio

6.3.5 Biocon Recent Developments/Updates

6.4 Novo Nordisk

6.4.1 Novo Nordisk Company Information

6.4.2 Novo Nordisk Description and Business Overview

6.4.3 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio

6.4.5 Novo Nordisk Recent Developments/Updates

6.5 Eli Lilly

6.5.1 Eli Lilly Company Information

6.5.2 Eli Lilly Description and Business Overview

6.5.3 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio

6.5.5 Eli Lilly Recent Developments/Updates

6.6 Tonghua Dongbao

6.6.1 Tonghua Dongbao Company Information

6.6.2 Tonghua Dongbao Description and Business Overview

6.6.3 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio

6.6.5 Tonghua Dongbao Recent Developments/Updates

6.7 United Laboratory

6.7.1 United Laboratory Company Information

6.7.2 United Laboratory Description and Business Overview

6.7.3 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2020-2025)

6.7.4 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio

6.7.5 United Laboratory Recent Developments/Updates

6.8 Jiangsu Wanbang

6.8.1 Jiangsu Wanbang Company Information

6.8.2 Jiangsu Wanbang Description and Business Overview

6.8.3 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio

6.8.5 Jiangsu Wanbang Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Oral Hypoglycemic Agents and Insulin Analogues Industry Chain Analysis

7.2 Oral Hypoglycemic Agents and Insulin Analogues Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Oral Hypoglycemic Agents and Insulin Analogues Production Mode & Process Analysis

7.4 Oral Hypoglycemic Agents and Insulin Analogues Sales and Marketing

7.4.1 Oral Hypoglycemic Agents and Insulin Analogues Sales Channels

7.4.2 Oral Hypoglycemic Agents and Insulin Analogues Distributors

7.5 Oral Hypoglycemic Agents and Insulin Analogues Customer Analysis

8 Oral Hypoglycemic Agents and Insulin Analogues Market Dynamics

8.1 Oral Hypoglycemic Agents and Insulin Analogues Industry Trends

8.2 Oral Hypoglycemic Agents and Insulin Analogues Market Drivers

8.3 Oral Hypoglycemic Agents and Insulin Analogues Market Challenges

8.4 Oral Hypoglycemic Agents and Insulin Analogues Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Sanofi Aventis

Ganlee

Biocon Ltd.

Novo Nordisk

Eli Lilly

Tonghua Dongbao

United Laboratory

Jiangsu Wanbang

List of Tables

Table 1. Global Oral Hypoglycemic Agents and Insulin Analogues Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Oral Hypoglycemic Agents and Insulin Analogues Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Oral Hypoglycemic Agents and Insulin Analogues Market Competitive Situation by Manufacturers in 2024

Table 4. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Oral Hypoglycemic Agents and Insulin Analogues Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Oral Hypoglycemic Agents and Insulin Analogues, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, Product Type & Application

Table 12. Global Key Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Oral Hypoglycemic Agents and Insulin Analogues by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Hypoglycemic Agents and Insulin Analogues as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2020-2025) & (K Units)

Table 18. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Region (2020-2025)

Table 19. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2026-2031) & (K Units)

Table 20. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Region (2026-2031)

Table 21. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region (2020-2025)

Table 23. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region (2026-2031)

Table 25. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2020-2025) & (K Units)

Table 27. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2026-2031) & (K Units)

Table 28. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2020-2025) & (K Units)

Table 32. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2026-2031) & (K Units)

Table 33. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units) by Type (2020-2025)

Table 51. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units) by Type (2026-2031)

Table 52. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2020-2025)

Table 53. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2026-2031)

Table 54. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2020-2025)

Table 57. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2026-2031)

Table 58. Global Oral Hypoglycemic Agents and Insulin Analogues Price (USD/Unit) by Type (2020-2025)

Table 59. Global Oral Hypoglycemic Agents and Insulin Analogues Price (USD/Unit) by Type (2026-2031)

Table 60. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units) by Application (2020-2025)

Table 61. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units) by Application (2026-2031)

Table 62. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2020-2025)

Table 63. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2026-2031)

Table 64. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2020-2025)

Table 67. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2026-2031)

Table 68. Global Oral Hypoglycemic Agents and Insulin Analogues Price (USD/Unit) by Application (2020-2025)

Table 69. Global Oral Hypoglycemic Agents and Insulin Analogues Price (USD/Unit) by Application (2026-2031)

Table 70. Sanofi-Aventis Company Information

Table 71. Sanofi-Aventis Description and Business Overview

Table 72. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product

Table 74. Sanofi-Aventis Recent Developments/Updates

Table 75. Ganlee Company Information

Table 76. Ganlee Description and Business Overview

Table 77. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product

Table 79. Ganlee Recent Developments/Updates

Table 80. Biocon Company Information

Table 81. Biocon Description and Business Overview

Table 82. Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Biocon Oral Hypoglycemic Agents and Insulin Analogues Product

Table 84. Biocon Recent Developments/Updates

Table 85. Novo Nordisk Company Information

Table 86. Novo Nordisk Description and Business Overview

Table 87. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product

Table 89. Novo Nordisk Recent Developments/Updates

Table 90. Eli Lilly Company Information

Table 91. Eli Lilly Description and Business Overview

Table 92. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product

Table 94. Eli Lilly Recent Developments/Updates

Table 95. Tonghua Dongbao Company Information

Table 96. Tonghua Dongbao Description and Business Overview

Table 97. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product

Table 99. Tonghua Dongbao Recent Developments/Updates

Table 100. United Laboratory Company Information

Table 101. United Laboratory Description and Business Overview

Table 102. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product

Table 104. United Laboratory Recent Developments/Updates

Table 105. Jiangsu Wanbang Company Information

Table 106. Jiangsu Wanbang Description and Business Overview

Table 107. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product

Table 109. Jiangsu Wanbang Recent Developments/Updates

Table 110. Key Raw Materials Lists

Table 111. Raw Materials Key Suppliers Lists

Table 112. Oral Hypoglycemic Agents and Insulin Analogues Distributors List

Table 113. Oral Hypoglycemic Agents and Insulin Analogues Customers List

Table 114. Oral Hypoglycemic Agents and Insulin Analogues Market Trends

Table 115. Oral Hypoglycemic Agents and Insulin Analogues Market Drivers

Table 116. Oral Hypoglycemic Agents and Insulin Analogues Market Challenges

Table 117. Oral Hypoglycemic Agents and Insulin Analogues Market Restraints

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

Table 121. Authors List of This Report

List of Figures

Figure 1. Product Picture of Oral Hypoglycemic Agents and Insulin Analogues

Figure 2. Global Oral Hypoglycemic Agents and Insulin Analogues Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Oral Hypoglycemic Agents and Insulin Analogues Market Share by Type: 2024 & 2031

Figure 4. Insulin Secretagogues Product Picture

Figure 5. Alpha-glucosidase Inhibitors Product Picture

Figure 6. Insulin Sensitizers Product Picture

Figure 7. Global Oral Hypoglycemic Agents and Insulin Analogues Market Value by Application (2020-2031) & (US$ Million)

Figure 8. Global Oral Hypoglycemic Agents and Insulin Analogues Market Share by Application: 2024 & 2031

Figure 9. Hospitals

Figure 10. Drug Store

Figure 11. Others

Figure 12. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size (2020-2031) & (US$ Million)

Figure 14. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (2020-2031) & (K Units)

Figure 15. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price (USD/Unit) & (2020-2031)

Figure 16. Oral Hypoglycemic Agents and Insulin Analogues Report Years Considered

Figure 17. Oral Hypoglycemic Agents and Insulin Analogues Sales Share by Manufacturers in 2024

Figure 18. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Manufacturers in 2024

Figure 19. Global 5 and 10 Largest Oral Hypoglycemic Agents and Insulin Analogues Players: Market Share by Revenue in Oral Hypoglycemic Agents and Insulin Analogues in 2024

Figure 20. Oral Hypoglycemic Agents and Insulin Analogues Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 21. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 22. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2020-2031)

Figure 23. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2020-2031)

Figure 24. U.S. Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Canada Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2020-2031)

Figure 27. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2020-2031)

Figure 28. Germany Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. France Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. U.K. Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Italy Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Russia Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Region (2020-2031)

Figure 34. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region (2020-2031)

Figure 35. China Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Japan Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. South Korea Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. India Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Australia Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. China Taiwan Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Indonesia Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Thailand Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Malaysia Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2020-2031)

Figure 45. Latin America Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2020-2031)

Figure 46. Mexico Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Brazil Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Argentina Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2020-2031)

Figure 50. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2020-2031)

Figure 51. Turkey Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. UAE Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Global Sales Market Share of Oral Hypoglycemic Agents and Insulin Analogues by Type (2020-2031)

Figure 55. Global Revenue Market Share of Oral Hypoglycemic Agents and Insulin Analogues by Type (2020-2031)

Figure 56. Global Oral Hypoglycemic Agents and Insulin Analogues Price (USD/Unit) by Type (2020-2031)

Figure 57. Global Sales Market Share of Oral Hypoglycemic Agents and Insulin Analogues by Application (2020-2031)

Figure 58. Global Revenue Market Share of Oral Hypoglycemic Agents and Insulin Analogues by Application (2020-2031)

Figure 59. Global Oral Hypoglycemic Agents and Insulin Analogues Price (USD/Unit) by Application (2020-2031)

Figure 60. Oral Hypoglycemic Agents and Insulin Analogues Value Chain

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions